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Abstract
Background: DNA hypermethylation and histone deacetylation are epigenetic events that contribute to the absence or
downregulated expression of different components of the tumor recognition complex. These events affect the processing and
presentation of antigenic peptides to CTLs by HLA class-I molecules. In this work evaluated the effect of the DNA
hypomethylating agent hydralazine and the histone deacetylase inhibitor valproic acid, on the expression of HLA class-I
molecules and on the antigen-specific immune recognition of cervical cancer cells.
Methods: Cell lines C33A (HPV-), CaSki (HPV-16+) and MS751 (HPV-18+) were treated with hydralazine and valproic acid
to assess the expression of HLA class-I molecules by flow cytometry and RT-PCR. Promoter methylation of HLA class-I -A,
-B and C, was also evaluated by Methylation-Specific PCR. Primary cervical tumors of four HLA-A*0201 allele patients were
typed for HPV and their CTL's stimulated in vitro with the T2 cell line previously loaded with 50 µM of the HPV peptides.
Cytotoxicity of stimulated CTL's was assayed against Caski and MS751 cells pre-treated with hydralazine and valproic acid.
Results: Valproic acid and hydralazine/valproic acid up-regulated the constitutive HLA class-I expression as evaluated by flow
cytometry and RT-PCR despite constitutive promoter demethylation at these loci. Hydralazine and valproic acid in
combination but no IFN-gamma hyperacetylated histone H4 as evaluated by ChiP assay. The antigenic immune recognition of
CaSki and MS751 cells by CTLs specific to HPV-16/18 E6 and E7-derived epitopes, was increased by VA and H/VA and the
combination of H/VA/IFN-gamma.
Conclusion: These results support the potential use of hydralazine and valproic acid as an adjuvant for immune intervention
in cervical cancer patients whenever clinical protocols based on tumor antigen recognition is desirable, like in those cases
where the application of E6 and E7 based therapeutic vaccines is used.
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Background
Aberrant gene transcription resulting from epigenetic
changes, -namely DNA promoter hypermethylation and
histone deacetylation- are frequent events in the molecu-
lar pathogenesis of malignant transformation [1,2].
Although cancer cells are less immunogenic than patho-
gens, the immune system is clearly capable of recognizing
and eliminating tumor cells. However, tumors frequently
interfere with immune response development and func-
tion through several mechanisms such as loss of antigen
processing and presentation, the Fas counterattacking sys-
tem, escaping from death receptor signaling, engaging in
inhibition-blocking activation, suppression of antitumor
responses by regulatory T cells, and tumor-induced
immune suppression [3].
Current research demonstrates that epigenetic defects are
involved in at least some mechanisms that preclude
mounting a successful host-antitumor response, involving
the HLA system, tumor-associated antigens, and acces-
sory/co-stimulatory molecules [4,5]. Presentation of anti-
gens within the context of HLA molecules is crucial both
during T-cell priming and the effector phase of an adap-
tive immune response. Genetic alterations in antigen
processing and presentation are commonly observed in
malignancies, thus, complete HLA loss is a common event
in several murine and human tumors [6,7]. DNA methyl-
ation participates in regulation of the expression of the
three classes of human leukocyte antigen class-I antigens:
HLA-A, HLA-B, and HLA-C, which are CpG-rich at their
gene promoters [8]. Nie et al. showed down-regulation of
HLA class-I antigens in esophageal carcinoma as a com-
mon mechanism for transcriptional inactivation caused
primarily by DNA hypermethylation [9], as well as in
melanoma, where 5-aza-2'-deoxycytidine significantly
enhances the constitutive expression of HLA class-I anti-
gens, of HLA-A1 and -A2 alleles, and of the co-stimulatory
molecule, intercellular adhesion molecule-1, and lym-
phocyte function-associated antigen-3 [10]. Regarding
HLA-Class-II, not only promoter hypermethylation
[11,12] but also histone deacetylation have been found to
account for the MHC-class-II-deficient phenotype of
tumor cells. The treatment of CIITA- and MHC-class-II-
deficient cells with the histone deacetylation agent tri-
chostatin A results in the induction of CIITA, and resulting
MHC class-II expression [13], in addition to the induction
of expression of several other immunologically important
molecules such as MHC class-I and CD40 [14].
Hydralazine (H), one of the first orally antihypertensive
developed, is also a non-nucleoside DNA methylation
inhibitor [15-17] whose demethylating and gene reacti-
vating activity in tumors has also been demonstrated in a
phase I trial in cervical cancer patients [18]. Valproic acid
(VA) an 8-carbon, branched-chained fatty acid well-
known as an effective antiepileptic drug causes hyper-
acetylation of the N-terminal tails of histones H3 and H4
in vitro and in vivo and inhibits HDAC activity [19,20]. Its
ability to inhibit deacetylase activity in solid tumors has
recently been demonstrated in cervical cancer patients
[21], and when used in combination, these epigenetic
agents show inhibitory growth effect in vitro and in vivo,
and a synergistic effect upon global gene expression [22].
E6 and E7 proteins of high-risk human (HPV) types are
thought to be the ideal sources of antigens for immuno-
therapy for cervical cancer because their persistence is nec-
essary to maintain the transformed cell phenotype,
moreover is known that E7 protein seems to induce pro-
tective cellular immunity in human premalignancy [23].
Since the majority of cervical cancer tumors show cells
with a dysregulated expression of HLA class-I molecules
on their surface that may affect the presentation of HPV-
derived antigenic peptides to cytotoxic T cells [24,25], in
this work we analyzed whether H and VA are able to up-
regulate the expression of HLA class-I molecules on cervi-
cal cancer cell lines and whether they can promote the
response to the presentation of known HPV16 E6 and E7-
derived antigenic peptides to cytotoxic T cells derived
from cervical cancer patients.
Methods
Cell lines and antibodies
C33A (HPV-), CaSki (HPV-16+) and MS751 (HPV-18+)
human cervical carcinoma cell lines, which express in
common the HLA-A2 allele on cell surface [26], as well as
the SW480 colon carcinoma cell line, were maintained in
RPMI-1640 medium (Gibco Laboratories, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum
(HyClone, Inc. Laboratories Logan Utah. USA), penicillin
G (100 IU/mL) (Lakeside, México), 100 µg/mL strepto-
mycin sulphate (Sigma Chem. Co. St. Louis Mo, USA),
and 2 mM L-glutamine (Sigma Chem. Co. St. Louis Mo,
USA). Monoclonal antibodies were obtained from hybri-
domas supernatants and purified by elution in Protein-G
sepharose (Sigma, Chem. Co. USA) columns: PA2.1 (Anti
HLA-A2, -A28) MAb was purchased from American Type
Culture Collection (Rockville, MD, USA) and the W6/32
MAb, which recognizes a conformational epitope on the
intact heavy chain/β2microglobulin complex, was gener-
ously supplied by Dr. Gerd Moldenhauer of the German
Cancer Research Center, Heilderberg, Germany.
Hydralazine and valproic acid cell treatment
Cervical cancer cell lines were cultured in the presence of
H, VA or both. Briefly: 5 × 105 cells were cultured in 6-well
plates in the presence of 10µM of H (Sigma, Chem. Co.
U.S.A) or 1 mM of VA (Sigma, Chem. Co. U.S.A) during 5
or 3 days respectively or with both drugs added together.
On day 3 of cell culture, 2 mL of medium were removedJournal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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and then added 2 mL of fresh complete medium contain-
ing the same concentration of drugs.
Flow cytometry
To determine HLA class-I molecule expression on cell sur-
face, 5 × 105 cells were treated with 10 µg/mL of each puri-
fied MAb, for 30 min. After washing the cells three times
in 0.15 M NaCl-0.01 M phosphate buffer (pH 7.2)-2%
fetal bovine serum (PBS-F), FITC-labeled goat anti-mouse
Ig antibody (Gibco Co. U.S.A) was added to a dilution of
1:100 for 20 min on ice, followed by another two washes
in PBS-F. Finally, the cells were resuspended in 0.5 mL of
PBS-F and 1 µg/mL of Propidium Iodide (Sigma Chem.
Co. USA) to discard cellular debris and then transferred to
tubes. Cell samples were analyzed in a FACS-calibur flow
cytometer (Becton Dickinson & Co. Mountain View, CA,
USA). After gating out cell debris, 10 000 events were ana-
lyzed for their fluorescence intensity. In all experiments,
the fluorescence intensity was determined at least three
times where each of the 10, 000 events were gated. The
staining with the FITC-labeled secondary antibody alone
was considered as a negative control. The effect of human
recombinant IFN-gamma on the HLA induction was
determined in cell lines cultured with or without the pres-
ence of 200 U/mL of IFN-gamma (Genzyme Diagnostics,
Cambridge, USA) for 48 hours [27]. The cells were then
harvested and their HLA expression was determined as
previously indicated.
RT-PCR
Elution buffer. The PCR-amplification was carried out
using the Advantage-GC Genomic PCR Kit (Clonetech)
according to the manufacturer's instructions. PCR primer
sequences for amplifying the human MHC class I pro-
moter are enlisted in table 1. PCR products were separated
on a 1.8% agarose gel and visualized by ethidium bro-
mide staining.
Stabilization assays of the HLA-A2 allele with HPV E6 and 
E7-derived peptides
The antigenic peptides TLGIVCPIC and YMLDLQPETT
derived from the E7 HPV-16 protein and the KLPDLCTEL
derived from the E6 HPV-18 protein that specifically bind
to HLA-A2 allele [28-30], were synthesized by Invitrogen,
USA, dissolved in phosphate buffered saline and stored at
-70°C before use. The peptide GILGFVFTL derived from
the M Influenza-A protein, was used as positive control for
binding assay to the empty HLA-A2 molecule. Lymphob-
lastic T2 cell line, which express empty HLA-A*0201 mol-
ecules on its cell surface [31], was used to test the affinity
of different concentrations (12.5–100 µM) of each syn-
thetic peptide after incubation overnight at 37°C in the
presence of 5 µg/mL of β2-microglobulin (Sigma, USA).
Clinical samples
Biopsies were taken from areas with visible macroscopic
cervical tumor using a sterile biopsy punch. Part of the
biopsy was sent to the Institution's Pathology Department
for routine hematoxilin & eosin diagnosis. The remaining
biopsy specimen was immediately frozen at -20°C for
HPV typing. In addition, 20 mL of peripheral blood were
drawn from the arm by venipuncture to obtain the mono-
nuclear cell fraction in order to stimulate the cytotoxic T
lymphocytes. The protocol was approved by the Institu-
tional Regulatory Boards and patients signed an informed
consent before blood and sample tissues were taken.
HPV typing
The MY09 and MY11 L1 consensus primers (Table 1) that
recognize a conserved region in the L1 open reading
frame, producing a fragment of 450 bp, were used to
examine the presence of HPV DNA in the genomic DNA
of each β-globin positive tumor sample.
The reaction was carried out in a final volume of 25 µL
containing 400 ng of DNA, 1.5 mM MgCl2, 200 µM of
dNTPs, 0.4 µM of each of the primers and 1U of Taq DNA
polymerase (GIBCO BRL, Grand Island, NY). The positive
control consisted of DNA from CaSki and MS751 cell
lines, which contain the HPV type 16 and 18 genome
respectively. The conditions of amplification were as fol-
lows: Denaturing at 94°C for 15 sec, primer annealing at
58°C for 30 sec and extension at 72°C for 1 min, for a
total of 35 cycles, the final cycle included an incubation at
Table 1: Primers and conditions used for PCR and RT-PCR analysis.
Primer set Sense 5'-3' Antisense 5'-3' Size pb Annealing
MHC-I promoter ccagttcagggacagagattacggg gagagggagaaaagaaactgcggag 280 60°C
HLA-A gacagcgacgccgcgagcca ggcagcgaccacagctccag 807 64°C
HLA-B gacagcgacgccgcgagtcc agtagcgaccacagctccga 907 60°C
HLA-C gagatcacactgacctggca gaacacagtcagtgtgggg 589 53°C
β-actin gggtcagaaggattcctatg ggtctcaaacatgatctggg 238 58°C
E7HPV16 cagctcagaggaggaggatg gcccattaacaggtcttcca 166 60°C
E6HPV18 atgctgcatgccataaatgt tgcccagctatgttgtgaaa 214 60°C
actin acacctggacctggactcac gctcttggctcctttgtcac 231 60°C
MY09 cgtccmarrggawactgatc 45°C
MY11 gcmcagggwcataayaatgg 450Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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72°C for 10 min. 7 µL of amplification product were elec-
trophoresed in 1.5% agarose containing 0.5 µg/mL of
ethidium bromide and visualized by UV light. Positive
MY09/MY11 products were digested with Bam HI and
Rsal restriction enzymes (Biolabs, USA). The restricted
samples were electrophoresed on a 3% agarose gel stained
with ethidium bromide. The restriction fragment length
polymorphism (RFLP's) obtained were compared with
that reported by Bernard [32].
In vitro induction of CTL responses
To stimulate CTLs, we used a method previously reported
[33]. Briefly: 4 × 106  Peripheral Blood Lymphocytes
(PBLs) were resuspend in 1 mL of complete medium con-
sisting of Iscove's Modified Dulbecco's Medium (Gibco
BRL, USA) supplemented with 10% heat-inactivated FBS,
100 IU/mL penicillin, 4 mM L-glutamine, 1 mM sodium
pyruvate and 20 µM 2-mercaptoethanol, and incubated
with 10 µM of peptide in 24-wells plates. On day 3, the
wells were topped up with 1 mL of complete medium
containing recombinant human IL-2 (final concentration
10 IU/mL, R&D). On day 7 and weekly thereafter, the cells
were restimulated as follows: (a) we used T2 cell line as
antigen presenting cell; 1 × 105 T2 cells previously loaded
with 50 µM of the peptides in the presence of β2-
microglobulin and fixed with 0.1% glutaraldeyde in PBS,
were incubated with 5 × 105 T cells; (b) 1 × 106 responder
T cells were added in 1 mL of complete medium; and (c)
cells were topped up 2 days later with 1 mL of complete
medium containing hrIL-2 and hrIL-15 at final concentra-
tion of 10 IU/mL and 15 ng/mL respectively. Cytotoxicity
assays were performed on day 21.
Cytotoxicity assays
Cervical cancer cell lines alone or pretreated with H, VA,
both, IFN-gamma or H/VA/IFN-gamma as indicated, were
used as target cells after labeled with 51Cr (Amersham,
USA) for 1 h. Different numbers of effector cells in 50 µL
of complete medium were incubated and then 2.5 × 103
51Cr-labeled target cells were added to triplicate wells of
96-well plates in final volume of 200 µL. After 4 h at
37°C, 100 µL of supernatant were harvested and trans-
ferred to counting vials and measured on a γ-counter
(Packard, U.S.A). For each pretreated cell group, 51Cr-
labeled cells incubated with 5% SDS or medium alone
were used to determine maximum and spontaneous
releases. Spontaneous release was usually less than 10%
and never exceeded 15%. The percentage of specific lysis
of each well was calculated as: (experimental release -
spontaneous release)/(maximal release - spontaneous
release) × 100.
Statistical analysis
All numerical data were expressed as average of values
obtained ± standard deviation (SD) of experiments made
by triplicate. Comparisons were evaluated by unpaired t
test. A p value <0.05 was considered significant.
Results
Hydralazine and valproic acid effects upon expression of 
HLA class-I molecules at the cell membrane
To determine whether these epigenetic agents enhance the
constitutive expression of HLA class-I molecules, the
expression analysis of the HLA-A2 allele and total HLA
class-I molecules was carried out by using PA2.1 and W6/
32 MAbs. The results showed that HLA-A2 allele expres-
sion level was unchanged in the C33A cells by hydralazine
alone whereas VA, H/VA, IFN-γ and H/VA/IFN-γ increased
one-fold its expression. Regarding total class-I molecules,
the increasing effect was unexistent except for a small
increase by IFN-γ and H/VA/IFN-γ. In CasKi cells, a similar
pattern of increased expression was observed in HLA-A2
allele and total HLA class-I molecules expression by these
drugs and combinations except for hydralazine alone
treatment. In particular for total HLA class-I, it seems there
was a summatory effect among the three drugs, H/VA/
IFN-γ. Of note the effect seen on CasKi cells in HLA-A2
allele and total HLA class-I molecules by these drugs and
combinations was almost identical in the MS751 cells.
Statistical significance among cell lines and treatments in
comparison to untreated (wt) are shown (Figure 1).
Transcriptional effect of hydralazine and valproic acid 
upon expression of HLA class-I molecules
To investigate whether the up-regulating effects of these
drugs of HLA class-I molecules as shown by flow cytome-
try could be mediated by increased transcription, treated
cell lines were analyzed by RT-PCR. Figure 2 shows that
C33A cells despite had no increase in transcript levels for
the HLA-A and -C genes with any combination of treat-
ments, HLA-B gene showed a 0.35, 0.29, 0.21 and 0.42
fold-increase in band intensities with H, VA, H/VA and H/
VA/IFN-gamma respectively. In CasKi cells where HLA-A2
was most increased by IFN-gamma and H/VA/IFN-
gamma the fold increases in band intensity were 0.13 and
0.91 respectively. HLA-B was also increased 0.12, 0.43 and
0.28-fold with H/VA, IFN-gamma and H/VA/IFN-gamma
respectively. In HLA-C, an increase of 0.25 and 1.4-fold
were observed with IFN-gamma and H/VA/IFN-gamma.
The MS751 cell line showed increases of the same magni-
tude in band intensities with all the combinations except
for H alone. In particular for HLA-A gene, the triple com-
bination of H/VA/IFN-gamma led to a 1.29-fold increase.
Methylation and acetylation of HLA Class-I genes
Previous studies have demonstrated that epigenetic mech-
anisms are main regulators of the expression of this class
of molecules and that both DNA methylation and HDAC
inhibitors demethylate and reactivate their expression. To
investigate this issue, we determined by methylation-spe-Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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Effect of H and VA on the expression of HLA class-I antigens on cervical cancer cells Figure 1
Effect of H and VA on the expression of HLA class-I antigens on cervical cancer cells. C33, CaSki and MS751 cells 
were incubated in the presence of H and VA and either HLA-A2 (A) or total HLA class-I (B) expression was determined by 
flow cytometry as indicated in materials and methods. The mean of 10 000 events is depicted in each cell treatment. Significant 
differences, * and ** were obtained in comparison to untreated cells (wt).
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Transcriptional effect of hydralazine and valproic acid upon expression of HLA class-I molecules Figure 2
Transcriptional effect of hydralazine and valproic acid upon expression of HLA class-I molecules. Total RNA was 
extracted from C33A, CaSki and MS751 cells treated with H, VA or H/VA. RT-PCR analysis was performed using HLA-A, -B or 
-C and β-actin primer pairs (Table 1). PCR products were then separated on a 3% agarose gel. One hundred-bp markers (MW) 
were run in the flanking lanes of each gel. Human recombinant IFN-gamma was used as a positive inducer of the HLA class I 
expression. RNA of the peripheral blood lymphocytes (PBL) from a normal donor, was used as a positive control. A is C33A, 
B is Caski and C corresponds to MS751 cell lines. Changes in expression as determined by densitometric analysis according to 
treatments are described in results.Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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cific PCR the methylation status at the gene promoter of
HLA-A, -B and -C genes in C33A, CasKi and MS751 cell
lines. As shown in figure 3a, there was complete demeth-
ylation at these three promoters in all the cell lines inves-
tigated. The absence of gene promoter at these genes
prompted us to analyze whether histone acetylation could
be responsible for the increase expression seen by the epi-
genetic drugs used. As shown in figure 3b, chromatin
immunoprecipitation assay showed that the combination
of H/VA but no IFN-γ led to H4 hyperacetylation at the
HLA-class-I promoter. Because hydralazine can be consid-
ered as a weak DNA methylation inhibitor and it has been
reported that 5-aza-2'-deoxycytidine does demethylate the
HLA-B promoter in the KYSE esophageal carcinoma cell
line, we searched the expression of HLA-A, -B and -C genes
and the promoter methylation status in several cell lines.
We found that the SW480 colon carcinoma cell line had
methylated the HLA-B locus. When this cell line was
treated with H, VA and H/VA, like to that observed for cer-
vical cancer cell lines, VA and H/VA led to small but clear
increase in expression level of the three loci, however, nei-
ther H nor 5-aza'-2'-deoxycytidine demethylated the HLA-
B locus (Figure 3c and 3d).
Treatment with VA and H/VA increase the immune 
recognition of cervical cancer cells by CTLs stimulated 
with HPV-16 and HPV-18 E6/E7 derived epitopes
To analyze whether the treatment of cervical cancer cells
with hydralazine and valproic acid is also able to increase
their immune recognition, T lymphocytes derived from
cervical cancer patients with HPV-16 or HPV-18 infection
and with the HLA-A2 allele in their HLA Class-I haplo-
type, were stimulated with three known E6 and E7 HPV
derived antigenic peptides, that specifically bind to the
HLA-A*0201 allele [28-30]. Two of the peptides
TLGIVCPIC and YMLDLQPETT were derived from the E7
HPV-16 protein and the other one KLPDLCTEL derived
from the E6 HPV-18 protein. We also used the lymphob-
lastic T2 cell line to stimulate T lymphocytes contained in
PBL's from patients with cervical cancer. Due to the fact
that the T2 cells express empty HLA-A2 molecules on their
cell surface [31], we previously performed peptide bind-
ing assays to analyze the binding affinities for these pep-
tides. Using 50–100 µM of these three peptides, we
observed an efficient stabilization of the HLA-A2 allele on
T2 cells similar to the one obtained with the control pep-
tide GILGFVFTL derived from the protein M of the influ-
enza-A and with high binding affinity to the HLA-A2 allele
(Figure 4). The T lymphocytes used were obtained from
four patients with cervical squamous cell carcinoma. Two
of those with HPV-16 infection (Patients 1, 2) and two
with HPV-18 infection (Patients 3 and 4) all positive for
the HLA-A*0201 allele (Table 2). The lymphocytes were
stimulated during three rounds with the T2 cells loaded
with the three antigenic peptides and then challenged
against CaSki or MS751 cells that were previously treated
with H, VA, H/VA, IFN-gamma and H/VA/IFN-gamma.
We observed as expected, that T lymphocytes from the
patients 1 and 2, that were positive for HPV-16 infection
and stimulated with T2 cells loaded with the peptides
TLGIVCPIC and YMLDLQPETT were able to lyse CaSki
cells (Figure 5) and that this cytotoxicity mainly increased
when the cells were previously treated with VA, H/VA,
IFN-gamma and H/VA/IFN-gamma. Of note cytotoxicity
was at least if not higher with any of these combinations
as compared to IFN-gamma alone. On the other hand the
T lymphocytes derived from the two patients with HPV-18
infection (Patients 3 and 4) and stimulated with the T2
cell line loaded with the peptide KLPDLCTEL, were able to
lyse MS751 cells. In patient 3, the higher cytotoxicity was
found with VA, H/VA and H/VA/IFN-gamma whereas in
patient 4, the cytotoxic effect on cells treated with H/VA,
IFN-γ and H/VA/IFN-gamma was essentially of the same
magnitud but higher than IFN-gamma alone. (Figure 5).
In all experiments T lymphocytes stimulated with the E6
and E7 epitopes were always capable to lyse the T2 cell
line loaded with the proper antigenic peptide (data not
shown). Moreover, we observed a very low T cell cytotoxic
activity on CaSki and MS751 cells when T lymphocytes
previously stimulated with the control peptide
GILGFVFTL were challenged against these cells
Hydralazine and valproic acid effects upon expression of 
HPV viral oncogenes
To investigate whether these epigenetic agents modulate
the expression of E6 and E7 genes in the Caski and MS751
cell lines, the expression of these genes was analyzed by
RT-PCR. The results show that neither E7 transcript of the
HPV-16 nor E6 transcript of the HPV-18 were changed by
drug treatment suggesting that the enhanced immune rec-
ognition of CaSki and MS751 cells by CTLs derived from
cervical cancer patients can be mainly due to the increased
presentation of antigenic peptides by the increased expres-
sion of HLA class-I molecules on cell surface rather than
by an increase in E6 or E7 peptides (figure 6).
Discussion
In this work we present evidence that the antigen-specific
recognition of cervical cancer cells by cytotoxic T lym-
phocytes, is enhanced by the treatment of the cancer cells
with the histone deacetylase inhibitor valproic acid alone
or in combination with the DNA methylation inhibitor
hydralazine. This effect can be attributed to the improved
antigen presentation on the cell surface as a result of at
least partially from increased transcription of HLA class-I
molecules in treated cells. Although up-regulation of
these class-I molecules has already been observed to occur
after cells are treated with a demethylating agent [10] or
with a histone deacetylase inhibitor [14] our results dem-
onstrate that in some cell lines and patients the up-regula-Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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Methylation and acetylation of HLA Class-I genes Figure 3
Methylation and acetylation of HLA Class-I genes. A. HLA-A, -B anc -C gene promoters were analyzed by MSP in the 
cervical cancer cell lines. The control for unmethylated reaction is modified DNA from normal lymphocytes and for methyl-
ated is the same DNA but methylated in vitro. B. Chromatin immunoprecipitation assay with an anti-H4 acetylated antibody in 
Caski cells. Treatment with H/VA but no IFN-gamma led to H4 hyperacetylation. C. RT-PCR analysis of HLA-A, -B and -C, 
after treatment with H, H/VA and H/VA in SW480 colon carcinoma cell line and D. MSP (only with methylated primers shown) 
of the HLA-B promoter in SW480 cells indicating the lack of demethylation by H and 5-aza-2'-deoxycytidine.Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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tion is higher with the combination as compared to the
individual effect of these drugs. A synegistic effect upon
cancer testis antigens NY-ESO-1 and MAGE-A3 expression
has been observed with 5-aza-2'-deoxycytidine and dep-
sipeptide [34] but not upon HLA class-I molecules. Here
we demonstrate that hydralazine and valproic acid syner-
gize in this regard. This observation is supported by our
previous study in which SW480 cells showed up-regula-
tion of major histocompatibility complex, class-I-related
only with the combined treatment but no with hydrala-
zine or valproic acid alone [22]. Interestingly, in CasKi
and MS751 cells H/V slightly increase the up-regulation
when added to IFN-γ, as compared to IFN-γ alone, a
potent and well-known inducer of HLA-class-I expression
[33].
HLA-A2 allele stabilization with peptides derived from the E6 and E7 proteins Figure 4
HLA-A2 allele stabilization with peptides derived from the E6 and E7 proteins. The lymphoblastic T2 cell line, 
which express empty HLA-A*0201 molecules on their cell surface, was loaded with different concentrations of the peptides: 
TLGIVCPIC and YMLDLQPETT derived from the E7 HPV-16 protein and KLPDLCTEL of the E6 HPV-18 protein. The peptide 
GILGFVFTL derived from the M Influenza-A protein, was used as positive control for binding assay. After incubation overnight 
with the peptides, conformational expression of the HLA-A2 allele was determined by flow cytometry using the PA2.1 MAb. 
MFI, mean fluorescence intensity.
Table 2: HLA class-I alleles of the patients with cervical cancer 
and their tumor characteristics.
Patient Diagnostic Clinical stage (*) HLA class-I haplotype HPV type
1 SCC IIIB A2, B53, Cw4
A68, B48, Cw3
16
2S C C I B 1 A2, B39, Cw3
A2, B60, Cw3
16
3S C C I I AA2, B38(16), Cw3
A2, B60(40), Cw3
18
4 SCC IIIB A2, B35, Cw4
A3, B41, Cw7
18
(*) FIGO clinical staging system.Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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CTL recognition of CaSki and MS751(HPV-18+) cell lines treated with H and VA Figure 5
CTL recognition of CaSki and MS751(HPV-18+) cell lines treated with H and VA. T lymphocytes derived from 
patients with squamous cervical cancer, positives either for HPV-16 or -18 infection (Table 2) were stimulated with the pep-
tides TLGIVCPIC and YMLDLQPETT of the E7 HPV-16 protein and the peptide KLPDLCTEL of the E6 HPV-18 protein 
respectively and their cytolytic activity was tested by a standard 4-h 51Cr release assay against CaSki(HPV-16+) or 
MS751(HPV-18+) without treatment (WT) or previously treated with H, VA or H plus VA as indicated.Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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Previous studies have reported that the de novo expression
of HLA class-I antigens induced by 5-aza-2'-deoxycytidine
seems to be a sporadic phenomenon, since it was
observed only in one melanoma cell line [35] and in a
human esophageal cell carcinoma cell line [9], but not in
a panel of HLA class-I-negative or HLA-A2-negative
melanoma cells [36]. Consistent with an up-regulatory
and not with a the de novo re-expression effect we also
observed that these three cervical cell lines showed basal
mRNA expression of HLA-A, -B and -C loci as well as con-
stitutive expression of antigen processing components
such as LMP-2, LMP-7, LMP-10 catalytic subunits of the
proteasome and the transporters TAP-1 and TAP-2 (data
not shown). It was of interest the observation that the
effect of hydralazine was consistent regarding the lack of
effect in the expression of HLA class-I molecules as in the
cervical cancer cell lines tested the HLA-A, -B and -C pro-
moters were unmethylated. Interestingly, despite 5-aza-2'-
deoxycytidine has shown the ability to demethylate HLA-
B locus in a an esophageal carcinoma cell line, both
hydralazine and the nucleoside analog which is the proto-
type demethylating agent failed to demethylate the pro-
moter in the SW480 cell line despite 5-aza-2'-
deoxycytidine increased gene expression. This clearly indi-
cates that at least in this model, chromatin remodelling by
histone acetylation predominates over methylation
regarding the regulation of gene expression.
Besides the well demonstrated antitumor effects of epige-
netic therapies achieved by restoring the expression of key
HPV-16 E7 and HPV-18 E6 gene expression in CaSki and MS751 cell lines treated with H and VA Figure 6
HPV-16 E7 and HPV-18 E6 gene expression in CaSki and MS751 cell lines treated with H and VA. Total RNA was 
extracted from CaSki and MS751 cell lines treated with either H, VA or H plus VA and then RT-PCR analysis for the HPV-16 
E7 and HPV-18 E6 gene expression in CaSki and MS751 was respectively performed using E7 and E6 primer pairs (Table 1). 
The effect of human recombinant IFN-γ and the sum of H/VA/IFN-γ was also tested.Journal of Translational Medicine 2006, 4:55 http://www.translational-medicine.com/content/4/1/55
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genes responsible of the malignant phenotype [2], the res-
toration of the defective expression of distinct compo-
nents of the "tumor recognition complex" through
epigenetic targeting of cancer cells results in their efficient
recognition and lysis by antigen-specific CTL. In fact, de
novo expression of selected cancer tumor antigens induced
by 5-aza-2'-deoxycytidine allowed specific CTL recogni-
tion of melanoma, lung cancer, esophageal cancer, mes-
othelioma, renal cell carcinoma and sarcoma cells [34,37-
39]. Furthermore, the up-regulated expression of HLA
class-I antigens and allospecificities observed in
melanoma cell lines after exposure to 5-aza-2'-deoxycyti-
dine resulted in their increased recognition by a gp 100-
specific HLA-A2-restricted CTL clone [40].
Accordingly, the treatment of Caski and MS751 cell lines
with H, VA, IFN-γ or H/VA/IFN-γ enhanced their specific
recognition by the patients CTL's raised against specific
related peptides (TLGIVCPIC and YMLDLQPETT) of the
E7 HPV-16 protein and (KLPDLCTEL) of E6 HPV-18 but
no against the control peptide. Interestingly, the cytotox-
icity was higher with VA or H/VA and the combination of
H/VA/IFN IFN-gamma suggesting that in our system chro-
matin remodeling by histone HA acetylation could be the
key determinant for the enhanced specific recognition of
cancer cells by CTLs. In fact, whereas histone acetyltrans-
ferases promote CIITA function in transactivation of MHC
genes, histone deacetylases [41] interfere with this CIITA
function following IFN-gamma induction. Of note, the
observed cytotoxicity was higher with VA than with IFN-
gamma. It is known that histone deacetylation impairs the
transactivation of MHC genes by IFN-gamma, accord-
ingly, in CaSki and MS751 cells, it seems that H/VA
slightly increase the expression.
The role of HPV genome DNA hypermetylation is cur-
rently being studied. Existing information suggests that
methylation status of viral oncogenes in lesions is perhaps
solely the result of their transcriptional activity level and
not a causal event for neoplastic progression [42]. Here we
also found no changes of HPV-16 E7 on CaSki cells and
HPV-18 E6 on MS751. This result is in line with observa-
tions that HLA-A*0201-restricted CTL clones against
HPV-16 E629–38 that recognize HPV-16 E6 antigens trans-
fected into B lymphoblastoid cells are unable to recognize
HLA-A*0201(+) HPV16 E6(+) cervical carcinoma cell
lines even when the level of endogenous HPV-16 E6 in
these cells was increased by transfection. In addition, the
defect in presentation of HPV16 E6 [25-27,40-43] corre-
lates with low level expression of HLA class-I, proteasome
subunits low molecular mass protein 2 and 7, and the
transporter proteins TAP1 and TAP2 in the cervical carci-
noma cell lines, suggesting that presentation of the
HPV16 E6 epitope in cervical carcinoma cell lines is lim-
ited by mechanisms other than the level of HPV16 E629–38
epitope availability [43].
To the best of our knowledge this is the first study show-
ing an up-regulated HLA class-I expression and antigen-
specific CTL response in cervical cancer cells following the
use of hydralazine and valproic acid. It will be of interest
to investigate whether epitopes derived from proteins
whose genes have been reactivated by hydralazine and
valproic acid, different from those derived from HPV
oncogenic proteins can be specific targets for CTL immune
recognition. In fact, ongoing laboratory data from our
group demonstrate that these drugs have the ability to
increase the expression of tumor associated antigens such
as MAGE and GAGE families in cervical cancer cell lines
(data not shown). In addition, this combination of epige-
netic agents may also help to avoid immune evasion strat-
egy of tumors by up-regulating the expression of the
major histocompatibility complex, class-I-related, a pow-
erful NKG2D ligand for NK cell-mediated antitumor
immunity [44] as we have observed it in a colon carci-
noma cell line treated with hydralazine and valproate
[22].
Conclusion
The development of more effective immunotherapy strat-
egies calls for a better understanding of among other, the
mechanisms underlying immune evasion by tumors cells
[45]. The results of this study suggest that use of epigenetic
drugs such as hydralazine and valproic acid could
improve immune interventions in clinical trials based on
E6 and E7 peptides, due to their up-regulating effect on
HLA class-I molecules.
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